<table>
<thead>
<tr>
<th>Title</th>
<th>Synthesis of Cyclic ADP-Carbocyclic-Xylose and its 3′′-OO-Methyl Analogue as Stable and Potent Ca2+-Mobilizing Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Kudoh, Takashi; Matsuda, Akira; Shuto, Satoshi; Murayama, Takashi; Ogawa, Yasuo</td>
</tr>
<tr>
<td>Citation</td>
<td>Nucleosides, Nucleotides and Nucleic Acids, 25(4-6), 583-599</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2006-04</td>
</tr>
<tr>
<td>Doc URL</td>
<td><a href="http://hdl.handle.net/2115/46970">http://hdl.handle.net/2115/46970</a></td>
</tr>
<tr>
<td>Type</td>
<td>article (author version)</td>
</tr>
<tr>
<td>File Information</td>
<td>366_NsNt_Kudo.pdf</td>
</tr>
</tbody>
</table>

Hokkaido University Collection of Scholarly and Academic Papers: HUSCAP
SYNTHESIS OF CYCLIC ADP-CARBOCYLIC-XYLOSE AND ITS 3”-O-METHYL ANALOGUE AS STABLE AND POTENT Ca^{2+}-MOBILIZING AGENTS

Takashi Kudoh, Takashi Murayama, Yasuo Ogawa, Akira Matsuda and Satoshi Shuto*

*Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan

bDepartment of Pharmacology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

Corresponding Author: Satoshi Shuto

Phone & Fax: +81-11-706-3769.

E-mail: shu@pharm.hokudai.ac.jp

This paper is dedicated to Professor Eiko Ohtsuka on the occasion of her 70th birthday.

ABSTRACT

We previously showed that 3”-deoxy-cyclic ADP-carbocyclic-ribose (3”-deoxy-cADPcR, 2) is a stable and highly potent analogue of cyclic ADP-ribose (cADPR, 1), a Ca^{2+}-mobilizing second messenger. From these results, we newly designed another 3”-modified analogues of cADPcR and identified the N1-“xylo”-type carbocyclic analogue, i.e., cADPcX (4), as one of the most potent cADPR-related compounds reported so far.

INTRODUCTION

Much attention has been focused on cyclic ADP-ribose (cADPR, 1, FIGURE 1), a naturally occurring metabolite of NAD^{+}, due to the biological interest. cADPR has been shown to mobilize intracellular Ca^{2+} in various cells, and is now recognized as a general mediator involved in Ca^{2+} signaling. Under neutral conditions, cADPR is in a zwitterionic form with a positive charge around the N(1)-C(6)-N^{6} moiety (pK_{a} = 8.3),
making the molecule unstable. The charged adenine moiety attached to the anomeric carbon of the N1-ribose can be an efficient leaving group. Accordingly, cADPR is readily hydrolyzed at the unstable N-1-ribosyl linkage of its adenine moiety to produce ADP-ribose (ADPR), even in neutral aqueous solution. Under physiological conditions, cADPR is also hydrolyzed at the N-1-ribosyl linkage by cADPR hydrolase to give the inactive ADPR.

cADPR analogues can be used in proving the mechanism of cADPR-mediated Ca\(^{2+}\) signaling pathways and are also expected to be lead structures for the development of drugs, since cADPR has been shown to play important physiological roles. Therefore, the synthesis of cADPR analogues has been extensively investigated by enzymatic and chemo-enzymatic methods using ADP-ribose cyclase-catalyzed cyclization. However, the analogues obtained by these methods are limited due to the substrate-specificity of the ADP-ribosyl cyclase.

On the other hand, in the chemical synthesis of cADPR and its analogues, construction of the large 18-membered ring structure is the key step, and we recently developed an efficient method for forming the 18-membered ring employing phenylthiophosphate-type substrates. When these substrates were activated by AgNO\(_3\) or I\(_2\) in the presence of molecular sieves in pyridine, the corresponding 18-membered ring products were obtained in high yields. Using this method, we successfully synthesized cyclic ADP-carbocyclic-ribose (cADPcR, 2), designed as a stable mimic of cADPR, in which the oxygen atom in the N-1-ribose ring of cADPR is replaced by a methylene group. Biological evaluation of cADPcR showed that it actually act as biologically and chemically stable equivalent of cADPR.

Based on these results, we have investigated further synthetic and biological studies on N1-carbocyclic derivatives of cADPR. In the course of these studies, we describe here the synthesis and biological evaluation of newly designed analogues of cADPcR, which are cyclic ADP-carbocyclic-xylose (cADPcX, 4) and the corresponding 3”-O-methyl derivative (3”-OMe-cADPcX, 5).

**RESULTS AND DISCUSSION**

**Design and Synthetic Plan.** We previously showed 1) that cADPcR (2) is actually resistant to both enzymatic and chemical hydrolysis, since it has a chemically and biologically stable N-alkyl linkage instead of the unstable N1-glycosidic linkage of cADPR, 2) that cADPcR has a conformation similar to that of cADPR, and 3) that cADPcR, like cADPR, effectively mobilizes intracellular Ca\(^{2+}\) in sea urchin eggs and neuronal cells. Furthermore, we have investigated SRA of the N1-ribose moiety of cADPcR and clarified that modification at the N1-ribose moiety changes the biological potency. Throughout these studies, we also found that although deletion of the 2”-hydroxy group resulted in a marked reduction of potency, deletion of the adjacent 3”-hydroxy group (3”-deoxy-cADPcR, 3) greatly potentiated the Ca\(^{2+}\)-mobilizing ability in sea urchin eggs. These results suggest that modification at the 3”-position may
improve the biological potency of cADPR and its analogues. Thus, we newly designed another 3"-modified analogues of cADPcR, which were the N1-“xylo”-type carbocyclic analogue, i.e., cADPcX (4) and the corresponding O-methyl analogue 5.

As described above, we have developed an efficient total synthetic method for cADPR analogues, 5 which we 6 and other groups 7 have effectively used in the synthesis of a variety of cADPR analogues. Thus, we planned to synthesize the target compounds based on the previous total synthetic method.

The synthetic plan is shown in SCHEME 1 as a retrosynthetic analysis. The chiral carbocyclic–xylosyl amines III, composing the N1-substituted moiety in the targets 4 and 5, could be prepared from commercially available (1R)-(−)-2-azabicyclo[2.2.1]hept-5-en-3-one (8). From these carbocyclic amines III and the known imidazole nucleoside derivative 6, 5b the 5’-phenylthiophosphate-type substrates II for the key intramolecular condensation could be prepared. Treatment of II with AgNO3/MS 3A as a promoter 5a,b was expected to form the cyclized products I, and subsequent acidic treatment for deprotection would furnish the desired cADPcR analogues 4 and 5.

Synthesis. The carbocyclic-xylosyl amine units 14a and 14b were synthesized from the optically active bicyclic lactam 8, as summarized in Scheme 2. After protection of the primary hydroxyl with a triisopropylsilyl (TIPS) group of cabocyclic-ribose derivative 9, prepared from 8 according to the previously reported method, 6c treatment of the resulting 10 under Mitsunobu reaction conditions with ClCH2CO2H/DIAD/Ph3P gave the corresponding 3-position-inverted product 11, and subsequent removal the 3-O-chloroacetly group with NaOMe/MeOH to afford the carbocyclic-xylose derivative 12. The 3-hydroxy of 12 was protected with a MOM group under usual conditions or methylated with MeOTf and 2,6-di-tert-butyl-4-methylpyridine (DTBMP), followed by removal of the TIPS group, to give the desired 3-O-MOM-protected unit 14a or the 3-O-methyl unit 14b, respectively.

The target 3"-modified cADPcR analogues 4 and 5 were successfully synthesized from the carbocyclic amines 14a or 14b and the imidazole nucleoside 6, as shown in SCHEME 3.

The N-1-substituted adenosine derivatives 15a and 15b were obtained in high yield by the treatment of a mixture of 6 and either amine 14a or amine 14b with K2CO3 in MeOH at room temperature. The 5”-hydroxy group of 15a or 15b was protected with a dimethoxytrityl (DMTr) group, and the 5’-O-TBS group of the product was subsequently removed with TBAF to give 16a or 16b. Treatment of 16a or 16b under the conditions reported by Hata and co-workers with an S,S’-diphenylphosphorodithioate (PSS)/2,4,6-triisopropylbenzenesulfonyl chloride (TPSCl)/pyridine system 6 gave the 5’-bis(phenylthio)phosphate 17a or 17b, respectively. The 5”-O-DMTr group of 17a or 17b was removed to give 18a or 18b, respectively. A phosphoryl group was introduced at the resulting 5”-primary hydroxyl of 18a or 18b by Yoshikawa’s method with POCl3/(EtO)3PO, 9 followed by treatment of the product with
H$_3$PO$_4$ and Et$_3$N$^{10}$ in the presence of $N$-methylmaleimide (NMM)$^{5c}$ in pyridine, to afford the corresponding 5’-phenylthiophosphate 19a or 19b, respectively, which was the substrate of the key intramolecular condensation reaction. When a solution of 19a in pyridine was added slowly to a mixture of a large excess of AgNO$_3$ and Et$_3$N in the presence of MS 3A in pyridine at room temperature,$^{5b,c}$ the intramolecular pyrophosphate linkage was successfully formed as the previously reported cases to give the desired cyclization product 20a in 46% yield. The other substrate 19b was similarly condensed and the cyclization product 19b was obtained. Finally, the protecting groups of 19a and 19b were simultaneously removed by acidic treatment with aqueous HCO$_2$H furnished the target cADPcX (4) and 3’’-OMe-cADPcX (5).

**Ca$^{2+}$-mobilizing Activity in Sea Urchin Egg Homogenate.** The Ca$^{2+}$-mobilizing ability of the newly synthesized compounds 4 and 5 was evaluated by the fluorometrically Ca$^{2+}$-monitoring method with *H. pulcherrimus* sea urchin egg homogenate,$^{6b,11}$ and the results were compared those of the natural second messenger cADPR (1) and the related carbocyclic analogues cADPcR (2) and 3’’-deoxy-cADPcR (3). Both of the two newly synthesized compounds 4 and 5 released Ca$^{2+}$ from the homogenate in a dose-dependent manner, as shown in FIGURE 2, where the maximal Ca$^{2+}$-mobilizing activity was almost equal to that of cADPR. Thus, 4 and 5 were shown to be full agonists as cADPcR (2) and 3’’-deoxy-cADPcR (3). cADPcX (4), the 3’’-epimer of cADPcR, showed marked Ca$^{2+}$-mobilizing activity with an EC$_{50}$ value of 69 nM, which was similar to that of cADPcR with an EC$_{50}$ value of 79 nM and was 3 times more potent than the natural ligand cADPR (EC$_{50}$ = 220 nM). The 3’’-O-methyl cADPcX (5) showed an EC$_{50}$ value of 740 nM, which was about 10 times weaker than cADPcX. Similar to the case of cADPcR, 3’’-methylation of the 3’’-hydroxy group of cADPcX markedly reduced the activity.

**CONCLUSION**

We successfully synthesized cADPcX (4), the 3’’-epimer of cADPcR (2), and the corresponding 3’’-O-methyl analogue (3’’-OMe-cADPcX, 5) and identified cADPcX as one of the most potent cADPR-related compounds reported so far. Therefore, irrespective of the 3’’-configuration, both cADPcX and cADPcR have strong Ca$^{2+}$-mobilizing activity to suggest that the 3’’-hydroxy group seems to be unnecessary in their binding with the target biomolecule, which is in accord with the previous results on the 3’’-deoxy-cADPcR with remarkable activity.$^{5c}$

**EXPERIMENTAL**

**General Methods.** Chemical shifts are reported in ppm downfield from Me$_4$Si (1H), MeCN ($^{13}$C) or H$_3$PO$_4$ ($^{31}$P). All of the $^1$H NMR assignments described were in agreement with COSY spectra. Thin-layer chromatography was done on Merck coated
Silica gel chromatography was done on Merck silica gel 5715. Reactions were carried out under an argon atmosphere.

(1R,2S,3R,4R)-1-tert-Butoxycarbonylamino-2-(methoxymethyloxy)-3-hydroxy-4-(triisopropylsilyloxymethyl)cyclopentane (10). A mixture of 9 (1.20 g, 4.12 mmol), TipSCI (2.12 mL, 9.88 mmol), imidazole (1.01 g, 14.8 mmol) and DMAP (0.604 g, 4.94 mmol) in DMF (40 mL) was stirred at room temperature for 4 h. After addition of MeOH (10 mL), the resulting mixture was evaporated. The residue was partitioned between EtOAc and H2O, and the organic layer was washed with brine, dried (Na2SO4), and evaporated. The residue was purified by column chromatography (SiO2, 25% EtOAc in hexane) to give 10 (1.68 g, 91%) as a colorless oil:

1H-NMR (CDCl3, 500 MHz) δ 4.98 (brs, 1H, NH), 4.78 (d, 1H, MOM-CH2, J = 6.4 Hz), 4.72 (d, 1H, MOM-CH2, J = 6.4 Hz), 4.08 (m, 1H, H-3), 3.99 (m, 1H, H-1), 3.88 (dd, 1H, H-6a, J6a,6b = 9.6 Hz, J6a,4 = 2.8 Hz), 3.80 (m, 1H, H-2), 3.69 (dd, 1H, H-6b, J6b,6a = 9.6 Hz, J6b,4 = 3.2 Hz), 3.41 (s, 3H, MOM-CH3), 2.66 (brs, 1H, OH), 2.37 (m, 1H, H-5a), 2.04 (m, 1H, H-4), 1.42 (s, 9H, tert-Bu), 1.33 (m, 1H, H-5b), 1.07-1.18 (m, 21H, TIPS); 13C-NMR (CDCl3, 125 MHz) δ 155.10, 96.53, 84.21, 79.13, 72.64, 63.66, 55.73, 53.62, 45.40, 30.33, 28.36, 18.00, 12.05; HRMS (FAB, positive) calcd for C22H46NO6Si 448.3094 (MH+), found 448.3109.

(1R,2S,3S,4R)-1-tert-Butoxycarbonylamino-2-(methoxymethyloxy)-3-(chloroacetoxy)-4-(triisopropylsilyloxymethyl)cyclopentane (11). To a mixture of 10 (0.160 g, 0.357 mmol), chloroacetic acid (0.135 g, 1.43 mmol), and Ph3P (0.374 g, 1.43 mmol) in toluene (2 mL), a solution of DIAD (281 µL, 1.43 mmol) in toluene (1.5 mL) was added slowly at 0 °C, and the mixture was stirred at room temperature for 6 h and then evaporated. The residue was purified by column chromatography (SiO2, 10% EtOAc in hexane) to give 11 (0.139 g, 74%) as a colorless oil:

1H-NMR (CDCl3, 500 MHz) δ 5.21 (dd, 1H, H-3, J3,2 = 3.9 Hz, J3,4 = 6.0 Hz), 4.86 (m, 1H, NH), 4.72 (d, 1H, MOM-CH2, J = 6.6 Hz), 4.69 (d, 1H, MOM-CH2, J = 6.6 Hz), 4.05 (s, 2H, Cl-Ac), 3.97 (m, 1H, H-1), 3.92 (m, 1H, H-2), 3.70 (m, 2H, H-6 x 2), 3.36 (m, 1H, MOM-CH2), 2.48 (m, 1H, H-4), 2.38 (m, 1H, H-5a), 1.43 (m, 10H, H-5b, tert-Bu), 1.09 (m, 21H, TIPS); 13C-NMR (CDCl3, 125 MHz) δ 166.33, 155.16, 95.70, 85.43, 79.78, 73.06, 70.82, 61.80, 55.48, 54.77, 41.55, 40.78, 32.43, 28.35, 17.95, 11.89; HRMS (FAB, positive) calcd for C24H46ClINO7Si 524.2810 (MH+), found 524.2816.

(1R,2S,3S,4R)-1-tert-Butoxycarbonylamino-2-(methoxymethyloxy)-3-hydroxy-
4-(triisopropylsilyloxy methyl)cyclopentane (12). A mixture of 11 (0.173 g, 0.330 mmol) and NaOMe (1 M in MeOH, 50 µL, 50 µmol) in MeOH (3 mL) was stirred at room temperature for 30 min. After addition of aqueous saturated NH$_4$Cl (1 mL) at 0 °C, the resulting mixture was extracted with EtOAc, and the organic layer was washed with H$_2$O and brine, dried (Na$_2$SO$_4$), and evaporated. The residue was purified by column chromatography (SiO$_2$, 25% EtOAc in hexane) to give 12 (0.130 g, 88%) as a colorless oil:

$^1$H-NMR (DMSO-$d_6$, 500 MHz) $\delta$ 6.69 (d, 1H, NH, $J = 7.3$ Hz), 4.70 (d, 1H, OH, $J = 4.6$ Hz), 4.63 (d, 1H, MOM-CH$_2$, $J = 6.4$ Hz), 4.60 (d, 1H, MOM-CH$_2$, $J = 6.4$ Hz), 3.84 (m, 2H, H-6a, H-3), 3.62 (m, 1H, H-1), 3.58 (m, 2H, H-2, H-6b), 3.22 (s, 3H, MOM-CH$_3$), 2.02 (m, 1H, H-4), 1.96 (m, 1H, H-5a), 1.36 (s, 10H, H-5b, tert-Bu), 1.03 (m, 21H, TIPS);

$^{13}$C-NMR (DMSO-$d_6$, 125 MHz) $\delta$ 156.04, 95.36, 88.30, 78.17, 74.92, 63.31, 55.46, 55.04, 43.62, 32.28, 28.56, 18.16, 11.67; HRMS (FAB, positive) calcd for C$_{22}$H$_{46}$NO$_6$Si 448.3094 (MH$^+$), found 448.3092.

(1R,2S,3S,4R)-1-tert-Butoxycarbonylamino-2,3-bis(methoxymethyloxy)-4-hydroxy methylcyclopentane (13a). A mixture of 12 (0.871 g, 1.95 mmol), MOMCl (739 µL, 9.73 mmol) and i-Pr$_2$NEt (3.39 mL, 19.5 mmol) in CH$_2$Cl$_2$ (20 mL) was stirred at room temperature for 75 h. After addition of MeOH (10 mL), the resulting mixture was evaporated. The residue was partitioned between EtOAc and 0.1 M HCl, and the organic layer was washed H$_2$O and brine, dried (Na$_2$SO$_4$), and evaporated. A mixture of the residue and TBAF (1.0 M in THF, 3.0 mL, 3.0 mmol) in THF (20 mL) was stirred at room temperature for 1 h and then evaporated. The residue was purified by column chromatography (SiO$_2$, EtOAc) to give 13a (0.634 g, 97%) as a yellow oil:

$^1$H-NMR (DMSO-$d_6$, 500 MHz) $\delta$ 6.85 (d, 1H, NH, $J = 7.9$ Hz), 4.64 (d, 1H, MOM-CH$_2$, $J = 6.5$ Hz), 4.59 (m, 3H, MOM-CH$_2$ x 3), 4.34 (m, 1H, OH), 3.84 (m, 1H, H-3), 3.80 (m, 1H, H-2), 3.66 (m, 1H, H-1), 3.50 (m, 1H, H-6a), 3.38 (m, 1H, H-6b), 3.26 (s, 3H, MOM-CH$_3$), 3.23 (s, 3H, MOM-CH$_3$), 2.06 (m, 1H, H-4), 1.93 (m, 1H, H-5a), 1.33 (s, 9H, tert-Bu), 1.32 (m, 1H, H-5b); $^{13}$C-NMR (DMSO-$d_6$, 125 MHz) $\delta$ 155.15, 95.36, 88.30, 78.17, 74.92, 63.31, 55.46, 55.04, 43.62, 32.28, 28.56, 18.16, 11.67; HRMS (FAB, positive) calcd for C$_{15}$H$_{29}$NO$_7$ (MH$^+$), found 448.3092.

(1R,2S,3S,4R)-1-tert-Butoxycarbonylamino-2-(methoxymethyloxy)-3-methoxy-4-hydroxymethylcyclopentane (13b). A mixture of 12 (0.513 g, 1.15 mmol), MeOTf (648 µL, 5.73 mmol) and DTBMP (1.29 g, 6.30 mmol) in CH$_2$Cl$_2$ (11 mL) was stirred at
room temperature for 12 h. After addition of aqueous saturated NaHCO$_3$ (10 mL) at 0 °C, the mixture was extracted with EtOAc, and the organic layer was washed with H$_2$O and brine, dried (Na$_2$SO$_4$), and evaporated. The residue was purified by column chromatography (SiO$_2$, 10% EtOAc in hexane) to give the 3-O-methylated product (0.259 g, 49%) as a colorless oil. A mixture of the oil and TBAF (1.0 M in THF, 0.84 mL, 0.84 mmol) in THF (5 mL) was stirred at room temperature for 2 h and then evaporated. The residue was purified by column chromatography (SiO$_2$, 75% EtOAc in hexane) to give 13b (0.154 g, 90%) as a yellow oil.

$^{1}$H-NMR (DMSO-d$_6$, 500 MHz) $\delta$ 6.84 (d, 1H, NH, $J = 8.0$ Hz), 4.65 (d, 1H, MOM-CH$_2$, $J = 6.5$ Hz), 4.58 (d, 1H, MOM-CH$_2$, $J = 6.5$ Hz), 3.65 (m, 1H, H-1), 3.47 (dd, 1H, H-3, $J_{3,2} = 3.0$ Hz, $J_{3,4} = 5.8$ Hz), 3.24 (s, 6H, OMe, MOM-CH$_3$), 2.04 (m, 1H, H-4), 1.91 (m, 1H, H-5a), 1.36 (s, 9H, tert-Bu), 1.30 (m, 1H, H-5b); $^{13}$C-NMR (DMSO-d$_6$, 125 MHz) $\delta$ 155.16, 94.70, 84.84, 84.45, 77.68, 59.93, 56.82, 55.69, 54.74, 42.65, 32.30, 28.39; FAB-MS m/z 306 (MH$^+$.); Anal. Calcd for C$_{14}$H$_{27}$NO$_6$: C, 55.07; H, 8.91; N, 4.59. Found: C, 55.09; H, 8.76; N, 4.51.

(1R,2S,3S,4R)-1-Amino-2,3-bis(methoxymethyloxy)-4-hydroxymethylcyclopentane (14a). A solution of 13a (0.614 g, 1.83 mmol) in H$_2$O (18 mL) was stirred at 100 °C for 12 h and then evaporated. The residue was azeotroped with toluene (10 mL x 3) to give 14a (0.430 g, quant.) as a brown oil.

$^{1}$H-NMR (DMSO-d$_6$, 500 MHz) $\delta$ 4.67 (d, 1H, MOM-CH$_2$, $J = 6.6$ Hz), 4.59 (m, 3H, MOM-CH$_2$ x 3), 3.85 (dd, 1H, H-3, $J_{3,2} = 3.5$ Hz, $J_{3,4} = 6.0$ Hz), 3.57 (m, 1H, H-2), 3.50 (dd, 1H, H-6a, $J_{6a,6b} = 10.3$ Hz, $J_{6a,4} = 7.0$ Hz), 3.37 (dd, 1H, H-6b, $J_{6b,6a} = 10.3$ Hz, $J_{6b,4} = 6.5$ Hz), 3.26 (s, 6H, OMe, MOM-CH$_3$), 2.96 (m, 1H, H-1), 2.06 (m, 1H, H-4), 1.92 (m, 1H, H-5a), 1.15 (s, 1H, H-5b); $^{13}$C-NMR (DMSO-d$_6$, 125 MHz) $\delta$ 95.24, 95.18, 89.75, 80.81, 60.41, 56.84, 54.98, 54.86, 42.57, 35.50; HRMS (FAB, positive) calcd for C$_{10}$H$_{22}$NO$_5$: C, 55.07; H, 8.91; N, 4.59. Found: C, 55.09; H, 8.76; N, 4.51.

(1R,2S,3S,4R)-1-Amino-2-(methoxymethyloxy)-3-methoxy-4-hydroxymethylcyclopentane (14b). Compound 14b (0.239 g, quant.) was obtained from 13b (0.351 g, 1.15 mmol) as described for the synthesis of 14a. $^{1}$H-NMR (DMSO-d$_6$, 500 MHz) $\delta$ 4.68 (d, 1H, MOM-CH$_2$, $J = 6.6$ Hz), 4.62 (d, 1H, MOM-CH$_2$, $J = 6.6$ Hz), 3.53 (m, 1H, H-2), 3.49 (m, 2H, H-3, H-6a), 3.33 (m, 1H, H-6b), 3.27 (s, 3H, MOM-CH$_3$ or OMe), 3.25 (s, 3H, MOM-CH$_3$ or OMe), 2.95 (m, 1H, H-1), 2.06 (m, 1H, H-4), 1.91 (m, 1H, H-5a), 1.14 (s, 1H, H-5b); $^{13}$C-NMR (DMSO-d$_6$, 125 MHz) $\delta$ 95.30, 89.03, 85.62, 60.28,
56.96, 56.91, 54.87, 42.50, 35.44; HRMS (FAB, positive) calcd for C_{29}H_{49}N_{5}O_{9}Si: C, 54.44; H, 7.72; N, 10.95. Found: C, 54.24; H, 7.66; N, 10.84.

\textbf{N-1-[(1R,2S,3S,4R)-2,3-Bis(methoxymethyl)oxy]-4-(dimethoxytrityloxymethyl)cyclopentyl]-2',3'-O-isopropylideneadenosine (16a).} A mixture of 15a (0.884 g, 1.38 mmol) and DMTriCl (1.40 g, 4.14 mmol) in pyridine (15 mL) was stirred at room temperature for 10 min. After addition of MeOH (10 mL), the resulting mixture was evaporated. The residue was purified by column chromatography (SiO\textsubscript{2}, 25% MeOH in EtOAc) to give 16a (0.93 g, 83%) as a white foam: \textit{\textbf{1H-NMR}} (CDCl\textsubscript{3}, 500 MHz) δ 7.91 (s, 1H, H-2 or H-8), 7.82 (s, 1H, H-2 or H-8), 6.02 (d, 1H, H-1', J\textsubscript{1',2'} = 2.7 Hz), 5.37 (m, 1H, H-1"), 5.09 (dd, 1H, H-2', J\textsubscript{2',1'} = 2.7 Hz, J\textsubscript{2',3'} = 6.1 Hz), 4.89 (dd, 1H, H-3', J\textsubscript{3',2'} = 6.1 Hz, J\textsubscript{3',4'} = 2.4 Hz), 4.81 (d, 1H, MOM-CH\textsubscript{2}, J = 6.6 Hz), 4.76 (d, 1H, MOM-CH\textsubscript{2}, J = 6.6 Hz), 4.69 (d, 1H, MOM-CH\textsubscript{2}, J = 6.9 Hz), 4.48 (m, 1H, H-2''), 4.39 (d, 1H, H-4', J\textsubscript{4',1} = 2.4 Hz, J\textsubscript{4',5a} = 6.4 Hz, J\textsubscript{4',5b} = 3.7 Hz), 4.19 (dd, 1H, H-3'', J\textsubscript{3'',4''} = 3.5 Hz, J\textsubscript{3'',5a} = 5.8 Hz), 3.83 (m, 2H, H-5'a, H-5''a), 3.77 (m, 2H, H-5'b, H-5''b), 3.45 (s, 3H, MOM-CH\textsubscript{3}), 3.21 (s, 3H, MOM-CH\textsubscript{3}), 2.47 (m, 1H, H-4''), 2.39 (m, 1H, H-6'a), 2.02 (m, 1H, H-6''b), 1.61, 1.39 (each s, each 3H, isopropylidene), 0.86 (s, 9H, tert-Bu), 0.046, 0.035 (each s, each 3H, TBS-Me x 2); \textit{\textbf{13C-NMR}} (CDCl\textsubscript{3}, 125 MHz) δ 154.45, 146.66, 140.62, 136.78, 123.40, 114.16, 96.39, 95.63, 91.26, 87.03, 85.32, 84.38, 81.76, 81.33, 63.46, 61.56, 60.08, 56.02, 55.49, 42.10, 31.22, 27.23, 25.86, 2 5.38, 18.32, -5.43, -5.54; FAB-MS \textit{m/z} 640 (MH\textsuperscript{+}); UV (MeOH) λ\textsubscript{max} = 261, 295 (sh) nm; Anal. Calcd for C\textsubscript{29}H\textsubscript{34}N\textsubscript{5}O\textsubscript{9}Si: C, 54.44; H, 7.72; N, 10.95. Found: C, 54.24; H, 7.66; N, 10.84.
by column chromatography (SiO₂, 25% MeOH in EtOAc) to give 16a (1.19 g, quant.) as a white foam: ¹H-NMR (CDCl₃, 500 MHz) δ 8.00 (s, 1H, H-2 or H-8), 7.62 (s, 1H, H-2 or H-8), 6.82-7.43 (m, 13H, DMTr), 5.79 (m, 2H, H-1’, H-1’’), 5.02 (m, 2H, H-2’, H-3’), 4.81 (d, 1H, MOM-CH₂, J = 6.9 Hz), 4.67 (d, 1H, MOM-CH₂, J = 6.9 Hz), 4.61 (d, 1H, MOM-CH₂, J = 6.7 Hz), 4.54 (d, 1H, MOM-CH₂, J = 6.7 Hz), 4.47 (d, 1H, MOM-CH₂, J = 6.7 Hz), 4.41 (m, 1H, H-4’), 4.38 (m, 2H, H-5’ x 2), 4.20 (d, 1H, H-3”), 4.20 (m, 1H, H-3”), 4.12 (m, 1H, H-2”), 3.91 (m, 1H, H-5’a), 3.80 (s, 6H, DMTr-OMe x 2), 3.72 (m, 1H, H-5”b), 3.30 (m, 1H, H-5”b), 2.68 (m, 1H, H-4”), 2.56 (m, 1H, H-6”a), 1.62, 1.35 (each s, each 3H, isopropylidene), 1.49 (m, 1H, H-6”b); ¹³C-NMR (CDCl₃, 125 MHz) δ 158.45, 146.70, 144.96, 137.95, 136.31, 136.11, 129.97, 129.93, 128.12, 127.79, 126.76, 114.20, 113.09, 113.06, 96.41, 94.93, 93.90, 86.00, 85.82, 83.61, 81.37, 61.53, 60.37, 58.81, 55.98, 55.60, 55.20, 42.94, 35.23, 27.55, 25.18, 21.02, 14.19; HRMS (FAB, positive) calcd for C₄₄H₅₄N₅O₁₁ 828.3820 (MH⁺), found 828.3818; UV (MeOH) λ_max = 260, 295 (sh) nm.

N-1-[(1R,2S,3S,4R)-2,3-Bis(methoxymethyloxy)-4-(dimethoxytrityloxymethyl)cyclopentyl]-5’-O-(bis(phenylthio)phospholyl)-2’,3’-O-isopropyldenedenosine (17a). After stirring a mixture of PSS (1.56 g, 4.09 mmol) and TPSCl (1.12 g, 3.69 mmol) in pyridine (14 mL) at room temperature for 1 h, 16a (1.13 g, 1.36 mmol) was added, and the resulting mixture was stirred at room temperature for further 2 h and then evaporated. The residue was partitioned between EtOAc and H₂O, and the organic layer was washed with brine, dried (Na₂SO₄), and evaporated. The residue was purified by column chromatography (SiO₂, 2% MeOH in CHCl₃) to give 17a (0.890 g, 65%) as a white foam: ¹H-NMR (CDCl₃, 500 MHz) δ 7.95 (s, 1H, H-2 or H-8), 7.64 (s, 1H, H-2 or H-8), 6.81-7.51 (m, 23H, DMTr, SPh x 2), 5.96 (d, 1H, H-1’, J₁,₂’ = 2.6 Hz), 5.76 (m, 1H, H-1”), 5.07 (dd, 1H, H-1”, J₁,₂” = 2.6 Hz, J₂,₃” = 6.3 Hz), 4.85 (dd, 1H, H-3’), J₁,₂” = 6.3 Hz, J₂,₃” = 2.7 Hz), 4.76 (d, 1H, MOM-CH₂, J = 6.8 Hz), 4.64 (d, 1H, MOM-CH₂, J = 6.8 Hz), 4.57 (d, 1H, MOM-CH₂, J = 6.7 Hz), 4.53 (d, 1H, MOM-CH₂, J = 6.7 Hz), 4.41 (m, 1H, H-4’), 4.38 (m, 2H, H-5’ x 2), 4.20 (d, 1H, H-3”), 4.14 (d, 1H, H-2”), 3.79 (s, 6H, DMTr-OMe x 2), 3.30 (m, 1H, H-5”a), 3.27 (s, 3H, MOM-CH₃), 3.19 (s, 3H, MOM-CH₃), 3.16 (m, 1H, H-5”b), 2.61 (m, 1H, H-4”), 2.54 (m, 1H, H-6”a), 1.59, 1.34 (each s, each 3H, isopropylidene), 1.54 (m, 1H, H-6”b); ¹³C-NMR (CDCl₃, 125 MHz)
$\delta$ 158.43, 154.52, 146.61, 144.99, 140.49, 136.94, 136.35, 136.17, 135.34, 135.29, 135.21, 135.17, 129.98, 129.96, 129.66, 129.63, 129.46, 129.44, 128.13, 127.76, 126.72, 125.93, 125.87, 125.79, 125.74, 123.52, 114.69, 113.05, 113.02, 95.88, 94.99, 90.61, 86.0 0, 85.87, 84.67, 84.61, 84.45, 81.06, 66.42, 66.36, 61.80, 58.76, 55.86, 55.51, 55.19, 42.79, 35.17, 27.13, 25.30, 21.02, 14.19; $^{31}$P-NMR (CDCl$_3$, 202 MHz) $\delta$ 50.74 (s); HRMS (FAB, positive) calcd for C$_{56}$H$_{63}$N$_5$O$_{12}$PS$_2$ 1092.3652 (MH$^+$), found 1092.3660; UV (MeOH) $\lambda_{max}$ = 295 (sh) nm.

$N$-1-[(1R,2S,3S,4R)-2,3-Bis(methoxymethoxy)-4-(hydroxymethyl)cyclopentyl]-5′-O-[bis(phenylthio)phosphoryl]-2′,3′-O-isopropylideneadenosine (18a). A solution of 17a (0.916 g, 0.839 mmol) in aqueous 60% AcOH (8 mL) was stirred at room temperature for 4 h. After addition of aqueous saturated NaHCO$_3$ (60 mL) at 0 °C, the mixture was extracted with EtOAc, and the organic layer was washed with aqueous saturated NaHCO$_3$, H$_2$O and brine, dried (Na$_2$SO$_4$), and evaporated. The residue was purified by column chromatography (SiO$_2$, 10% MeOH in CHCl$_3$) to give 18a (0.551 g, 83%) as a white foam: $^1$H-NMR (CDCl$_3$, 500 MHz) $\delta$ 7.93 (s, 1H, H-2 or H-8), 7.69 (s, 1H, H-2 or H-8), 7.30-7.52 (m, 10H, SPh x 2), 5.99 (m, 1H, H-1′), 5.32 (m, 1H, H-1′′), 5.11 (m, 1H, H-2′′), 4.90 (dd, 1H, H-3′, $J_{3′,2′}$ = 6.2 Hz, $J_{3′,4′}$ = 2.5 Hz), 4.76 (d, 1H, MOM-CH$_2$, $J$ = 6.5 Hz), 4.72 (d, 1H, MOM-CH$_2$, $J$ = 6.5 Hz), 4.66 (d, 1H, MOM-CH$_2$, $J$ = 6.5 Hz), 4.62 (d, 1H, MOM-CH$_2$, $J$ = 6.7 Hz), 4.45 (m, 1H, H-2′′), 4.43 (m, 2H, H-4′, H-5′a), 4.38 (m, 1H, H-5′b), 4.18 (m, 1H, H-3′), 3.84 (dd, 1H, H-5′a, $J_{5′a,5′b}$ = 11.2 Hz, $J_{5′a,5′b}$ = 3.8 Hz), 3.76 (dd, 1H, H-5′b, $J_{5′b,5′a}$ = 11.2 Hz, $J_{5′b,5′a}$ = 5.9 Hz), 3.41 (s, 3H, MOM-CH$_3$), 3.19 (s, 3H, MOM-CH$_3$), 2.47 (m, 1H, H-4′′), 2.40 (m, 1H, H-6′′a), 2.04 (m, 1H, H-6′′b), 1.60, 1.36 (each s, each 3H, isopropylidene); $^{13}$C-NMR (CDCl$_3$, 125 MHz) $\delta$ 154.27, 153.69, 137.38, 135.31, 135.27, 135.17, 135.13, 129.69, 129.66, 129.64, 129.62, 129.44, 129.42, 125.87, 125.82, 125.77, 125.72, 114.66, 96.35, 95.77, 90.74, 84.74, 84.68, 84.43, 81.64, 81.12, 66.39, 66.32, 61.49, 55.95, 55.50, 42.02, 31.10, 27.11, 25.29; $^{31}$P-NMR (CDCl$_3$, 202 MHz) $\delta$ 51.10 (s); FAB-MS $m/z$ 790 (MH$^+$); UV (MeOH) $\lambda_{max}$ = 259, 295 (sh) nm; Anal. Calcd for C$_{35}$H$_{44}$N$_5$O$_{12}$PS$_2$: C, 53.22; H, 5.61; N, 8.87. Found: C, 53.20; H, 5.66; N, 8.68.

$N$-1-[(1R,2S,3S,4R)-2,3-Bis(methoxymethoxy)-4-(phosphonomethyl)cyclopentyl]-5′-O-[(phenylthio)phosphoryl]-2′,3′-O-isopropylideneadenosine (19a). A mixture of POCl$_3$ (93 µL, 1.0 mmol) and 18a (79 mg, 0.10 mmol) in PO(OEt)$_3$ (1.0 mL)
was stirred at 0 °C for 1 h. After addition of aqueous saturated NaHCO₃ (3.0 mL), the resulting mixture was stirred at 0 °C for 10 min. To the mixture was added triethylammonium acetate (TEAA, 2.0 M, pH 7.0, 1.0 mL) buffer and H₂O (5.0 mL), and the resulting solution was applied to a C₁₈ reversed phase column (1.1 × 14 cm). The column was developed using a linear gradient of 0–65% MeCN in TEAA buffer (0.1 M, pH 7.0, 400 mL). Appropriate fractions were evaporated, and excess TEAA was removed by C₁₈ reversed phase column chromatography (1.1 × 17 cm, eluted with 70% aqueous MeCN). Appropriate fractions were evaporated, and the residue was co-evaporated with pyridine (2.0 mL x 3). A mixture of the residue, NMM (77 mg, 0.69 mmol), H₃PO₂ (70 µL, 1.39 mmol), and Et₃N (97 µL, 0.69 mmol) was stirred at 0 °C for 4 h under shading. After addition of TEAA buffer (1.0 M, pH 7.0, 2.0 mL), the resulting mixture was evaporated. The residue was partitioned between EtOAc and H₂O, and the aqueous layer was evaporated. A solution of the residue in H₂O (5.0 mL) was applied to a C₁₈ reversed phase column (1.1 × 16 cm), and the column was developed using a linear gradient of 0–40% MeCN in TEAA buffer (0.1 M, pH 7.0, 400 mL). Appropriate fractions were evaporated, and excess TEAA was removed by C₁₈ reversed phase column chromatography (1.1 × 17 cm, eluted with 50% aqueous MeCN). Appropriate fractions were evaporated, and the residue was lyophilized to give 19a (41 mg, 46%) as a triethylammonium salt: 

**¹H-NMR (D₂O, 500 MHz)** δ 8.71 (s, 1H, H-2 or H-8), 8.40 (s, 1H, H-2 or H-8), 7.01-7.30 (m, 5H, SPh), 6.31 (d, 1H, H-1’, J₁,2’ = 2.1 Hz), 5.33 (dd, 1H, H-2’, J₂,2’ = 2.1 Hz, J₂,3’ = 6.0 Hz), 5.00 (m, 1H, H-1”), 4.94 (dd, 1H, H-3’, J₁,2’ = 6.0 Hz, J₂,3’ = 1.2 Hz), 4.86 (s, 2H, MOM-CH₂), 4.72 (d, 1H, MOM-CH₂, J = 7.3 Hz), 4.70 (m, 1H, H-4”), 4.68 (d, 1H, MOM-CH₂, J = 7.3 Hz), 4.51 (m, 1H, H-2”), 4.33 (m, 1H, H-3”), 4.15 (m, 2H, H-5’ x 2), 4.07 (m, 2H, H-5” x 2), 3.48 (s, 3H, MOM-CH₃), 3.27 (s, 3H, MOM-CH₃), 3.18 (q, 6H, Et₃NH-CH₂ x 3, J = 7.3 Hz), 2.74 (m, 1H, H-4”), 2.68 (m, 1H, H-6”a), 2.08 (m, 1H, H-6”b), 1.62, 1.39 (each s, each 3H, isopropylidene), 1.26 (t, 9H, Et₃NH-CH₃ x 3, J = 7.3 Hz); 

**¹³C-NMR (D₂O, 125 MHz)** δ 151.02, 146.31, 146.10, 143.91, 133.21, 133.17, 129.90, 129.85, 129.44, 128.28, 119.61, 115.17, 97.10, 96.75, 91.87, 87.05, 86.67, 86.59, 84.64, 81.91, 80.44, 66.27, 63.81, 56.40, 56.14, 47.12, 40.75, 40.68, 26.38, 24.73, 8.69; 

**³¹P-NMR (D₂O, 202 MHz)** δ 17.10 (s), 0.84 (s); HRMS (FAB, positive) calcd for C₂₉H₄₂N₂O₁₄P₂S 778.1919 (MH⁺), found 778.1934; UV (H₂O) λ_max 260 nm.

**2”,3”-Bis-O-Methoxymethyl-cyclic ADP-carbocyclic-xylose 2’,3’-Acetonide**
To a mixture of AgNO$_3$ (310 mg, 1.83 mmol), Et$_3$N (255 µL, 1.83 mmol), and MS 3A (400 mg) in pyridine (70 mL), a solution of 19a (76 mg, 0.087 mmol) in pyridine (70 mL) was added slowly over 15 h, using a syringe-pump, at room temperature under shading. The MS 3A was filtered off with Celite and washed with H$_2$O. To the combined filtrate and washings was added TEAA buffer (2.0 M, pH 7.0, 2 mL), and the resulting solution was evaporated. The residue was partitioned between EtOAc and H$_2$O, and the aqueous layer was evaporated. A solution of the residue in H$_2$O (5.0 mL) was applied to a C$_{18}$ reverse phase column (1.1 × 17 cm), and the column was developed using a linear gradient of 0–25% MeCN in TEAA buffer (0.1 M, pH 7.0, 400 mL). Appropriate fractions were evaporated, and excess TEAA was removed by C$_{18}$ reverse phase column chromatography (1.1 × 17 cm, eluted with 40% aqueous MeCN). Appropriate fractions were evaporated, and the residue was lyophilized to give 20a (40 mg, 46%) as a triethylammonium salt:

$^1$H-NMR (D$_2$O, 500 MHz) δ 9.20 (s, 1H, H-2 or H-8), 8.44 (s, 1H, H-2 or H-8), 6.41 (d, 1H, H-1', $J_{1',2'} = 1.6$ Hz), 5.53 (dd, 1H, H-2', $J_{2',3'} = 6.1$ Hz), 5.46 (dd, 1H, H-3', $J_{3',2'} = 6.1$ Hz, $J_{3',4'} = 2.5$ Hz), 5.04 (m, 1H, H-1"), 4.80 (s, 2H, MOM-CH$_2$), 4.76 (d, 1H, MOM-CH$_2$, $J = 6.9$ Hz), 4.67 (d, 1H, MOM-CH$_2$, $J = 6.9$ Hz), 4.63 (m, 1H, H-4"), 4.62 (m, 1H, H-2"), 4.37 (m, 1H, H-3"), 4.23 (m, 1H, H-5"a), 4.16 (m, 1H, H-5’a), 4.09 (m, 2H, H-5”b, H-5”b), 3.42 (s, 3H, MOM-CH$_3$), 3.11 (s, 3H, MOM-CH$_3$), 3.19 (q, 6H, Et$_3$NH-CH$_3$ x 3, $J = 7.3$ Hz), 2.99 (m, 1H, H-6”a), 2.76 (m, 1H, H-4”), 2.36 (m, 1H, H-6”b), 1.64, 1.44 (each s, each 3H, isopropylidene), 1.27 (t, 9H, Et$_3$NHH-CH$_3$ x 3, $J = 7.3$ Hz); $^{13}$C-NMR (D$_2$O, 125 MHz) δ 151.93, 146.22, 146.28, 144.80, 119.64, 115.13, 97.69, 96.82, 92.47, 88.26, 86.92, 86.82, 85.13, 81.87, 81.29, 64.82, 64.61, 60.93, 56.25, 47.10, 37.29, 37.21, 28.70, 26.43, 24.74, 8.67; $^{31}$P-NMR (D$_2$O, 202 MHz) δ −9.58 (d, $J = 11.2$ Hz), −10.56 (d, $J = 11.2$ Hz); HRMS (FAB, positive) calcd for C$_{23}$H$_{36}$N$_5$O$_{14}$P$_2$ 668.1729 (MH$^+$), found 668.1730; UV (H$_2$O) $\lambda_{max}$ 259 nm.

**Cyclic ADP-carbocyclic-xylose (4).** A solution of 20a (31 mg, 0.040 mmol) in aqueous 80% HCO$_2$H (1 mL) was stirred at room temperature for 48 h and then evaporated. After evaporation of the residue in H$_2$O and i-PrOH, aqueous 28% NH$_3$ (1 mL) was added to the residue, and the mixture was stirred at room temperature for 90 min. After evaporation of the residue in H$_2$O and i-PrOH, the resulting residue was dissolved in TEAB buffer (0.1 M, pH 7.0, 600 µL), and the solution was lyophilized to give 4 (21 mg, 90%) as a triethylammonium salt: $^1$H-NMR (D$_2$O, 500 MHz, K$^+$ salt) δ
of methyl)cyclotriphosphazene (15b). Compound 15b (0.565 g, 84%) was obtained from 6 (0.480 g, 1.10 mmol) and 14b (0.227 g, 1.11 mmol) as described for the synthesis of 15a: 1H-NMR (CDCl3, 500 MHz) δ 7.91 (s, 1H, H-2 or H-8), 7.83 (s, 1H, H-2 or H-8), 6.02 (d, 1H, H-1”, J1’,2’ = 2.6 Hz), 5.54 (m, 1H, H-3’), 5.11 (dd, 1H, J2’,3’ = 2.6 Hz, J2’,3’ = 6.1 Hz), 4.89 (dd, 1H, H-3’, J3’-2’ = 6.1 Hz, J3’-4’ = 2.5 Hz), 4.74 (d, 1H, MOM-CH2, J = 6.8 Hz), 4.65 (d, 1H, MOM-CH2, J = 6.8 Hz), 4.39 (dd, 1H, H-4’, J4’,3’ = 2.5 Hz, J4’,5’a = 3.7 Hz, J4’,5’b = 6.3 Hz), 4.35 (m, 1H, H-2”), 3.90 (dd, 1H, H-5’a, J5’a,4’a = 3.0 Hz, J5’a,5’b = 11.3 Hz), 3.84 (dd, 1H, H-5’a, J3’-4’ = 3.8 Hz, J5’a,5’b = 11.2 Hz), 3.79 (m, 2H, H-3”, H-5’b), 3.76 (m, 1H, H-5”b), 3.50 (s, 3H, MOM-CH3 or OMe), 3.25 (s, 3H, MOM-CH3 or OMe), 2.42 (m, 2H, H-4”, H-6”a), 2.08 (m, 1H, H-6”b), 1.61, 1.39 (each s, each 3H, isopropylidene), 0.86 (s, 9H, tert-Bu), 0.048, 0.037 (each s, each 3H, TBS-Me x 2); 13C-NMR (CDCl3, 125 MHz) δ 154.48, 146.35, 140.70, 136.89, 123.26, 114.17, 95.33, 91.27, 87.04, 86.99, 85.28, 83.40, 81.34, 63.45, 61.54, 59.37, 57.70, 55.51, 42.02, 31.65, 27.22, 25.86, 25.37, 18.32, –5.43, –5.54; FAB-MS m/z 610 (MH+); Anal. Calcd for C28H24N5O5Si: C, 55.15; H, 7.77; N, 11.48. Found; C, 54.95; H, 7.59; N, 11.26.

N-1-[(1R,2S,3S,4R)-2-(Methoxymethyloxy)-3-methoxy-4-(dimethoxytrityloxy methyl)cyclopentyl]-2’,3’-O-isopropylideneadenosine (16b). Compound 16b (0.697 g, quant.) was obtained from 15b (0.527 g, 0.864 mmol) as described for the synthesis of 16a: 1H-NMR (CDCl3, 500 MHz) δ 7.92 (brs, 1H, H-2 or H-8), 7.62 (brs, 1H, H-2 or H-8), 6.82-7.45 (m, 13H, DMTr), 5.78 (m, 2H, H-1’, H-1”), 5.02 (m, 2H, H-2’, H-3’), 4.82 (d, 1H, MOM-CH2, J = 6.7 Hz), 4.68 (d, 1H, MOM-CH2, J = 6.7 Hz), 4.49 (m, 1H,
H-4’), 4.11 (m, 1H, H-2’), 3.91 (m, 1H, H-3’), 3.80 (s, 7H, H-5’a, DMT-methoxy x 2), 3.75 (m, 1H, H-5’b), 3.37 (s, 3H, MOM-CH3 or OMe), 3.35 (s, 3H, MOM-CH3 or OMe), 3.25 (m, 1H, H-5”a), 3.19 (m, 1H, H-5’b), 2.56 (m, 1H, H-4”), 2.48 (m, 1H, H-6”a), 1.62, 1.36 (each s, each 3H, isopropylidene), 1.46 (m, 1H, H-6”b); 13C-NMR (CDCl3, 125 MHz) δ 180.59, 165.74, 163.74, 152.56, 152.49, 144.47, 142.10, 141.56, 140.21, 136.11, 124.30, 122.87, 122.84, 99.99, 98.40, 88.24, 87.29, 86.38, 85.52, 84.71, 84.64, 84.45, 81.04, 66.45, 66.38, 61.23, 58.69, 57.39, 55.56, 55.19, 43.12, 35.07, 27.13, 25.30, 11.44; 31P-NMR (CDCl3, 202 MHz) δ 48.14 (s); FAB-MS m/z 1062 (MH+); UV (MeOH) λmax = 295 (sh) nm; Anal. Calcd for C55H60N5O11PS2: C, 62.19; H, 5.69; N, 6.59. Found; C, 62.34; H, 5.83; N, 6.34.

N-1’-[1R,2S,3S,4R]-2-(Methoxymethyloxy)-3-methoxy-4-(dimethoxytrityloxy methyl)cyclopentyl]-5’-O-[bis(phenylthio)phosphoryl]-2’,3’-O-isopropylidenedenosine (17b). Compound 17b (0.539 g, 62%) was obtained from 16b (0.659 g, 0.826 mmol) as described for the synthesis of 17a: 1H-NMR (CDCl3, 500 MHz) δ 7.91 (s, 1H, H-2 or H-8), 7.64 (s, 1H, H-2 or H-8), 6.81-7.51 (m, 23H, DMTr, SPh x 2), 5.96 (d, 1H, H-1’, J1’,2’ = 2.6 Hz, J2’,J1’ = 2.6 Hz, J2’,J3’ = 6.3 Hz), 5.76 (m, 1H, H-1””), 5.08 (dd, 1H, H-2’, J2’,J1’ = 2.6 Hz, J2’,J3’ = 6.3 Hz), 4.86 (dd, 1H, H-3’, J3’,J2’ = 6.3 Hz, J3’,J4’ = 2.7 Hz), 4.79 (d, 1H, MOM-CH2, J = 6.8 Hz), 4.63 (d, 1H, MOM-CH2, J = 6.8 Hz), 4.41 (m, 3H, H-4’, H-5’ x 2), 4.11 (m, 1H, H-2”), 3.79 (s, 6H, DMTr-OMe x 2), 3.78 (m, 1H, H-3”), 3.33 (s, 3H, MOM-CH3 or OMe) , 3.30 (s, 3H, MOM-CH3 or OMe), 3.25 (m, 1H, H-5”a), 3.18 (m, 1H, H-5”b), 2.54 (m, 1H, H-4”), 2.47 (m, 1H, H-6”a), 1.59, 1.35 (each s, each 3H, isopropylidene), 1.48 (m, 1H, H-6”b); 13C-NMR (CDCl3, 125 MHz) δ 158.38, 154.52, 146.79, 145.20, 140.52, 136.97, 136.42, 136.38, 135.34, 135.29, 135.22, 135.18, 130.04, 130.02, 129.65, 129.63, 129.43, 128.15, 127.69, 126.63, 125.94, 125.89, 125.82, 125.77, 123.51, 114.69, 113.00, 112.98, 95.09, 90.65, 85.79, 85.23, 84.71, 84.64, 84.45, 81.04, 66.45, 66.38, 61.23, 58.69, 57.39, 55.56, 55.19, 43.12, 35.07, 27.13, 25.30, 11.44; 31P-NMR (CDCl3, 202 MHz) δ 48.14 (s); FAB-MS m/z 1062 (MH+); UV (MeOH) λmax = 295 (sh) nm; Anal. Calcd for C55H60N5O11PS2: C, 62.19; H, 5.69; N, 6.59. Found; C, 62.34; H, 5.83; N, 6.34.

N-1’-[1R,2S,3S,4R]-2-(Methoxymethyloxy)-3-methoxy-4-(hydroxymethyl)cyclopentyl]-5’-O-[bis(phenylthio)phosphoryl]-2’,3’-O-isopropylidenedenosine (18b). Compound 18b (0.312 g, 88%) was obtained from 17b (0.496 g, 0.467 mmol) as described for the synthesis of 18a: 1H-NMR (CDCl3, 500 MHz) δ 7.92 (s, 1H, H-2 or H-8), 7.69 (s, 1H, H-2 or H-8), 7.31-7.52 (m, 10H, SPh x 2), 5.99 (d, 1H, H-1’, J1’,2’ =
described for the synthesis of Compound \( \text{cyclopentyl} \). Found: C, 53.59; H, 5.60; N, 8.97.

\[ \text{UV (MeOH)} \lambda_{\text{max}} = 259, 295 \text{ (sh) nm; Anal. Calcd for } C_{3}H_{4}N_{5}O_{9}PS_{2}: C, 53.75; H, 5.57; N, 9.22. \text{Found: C, 53.59; H, 5.60; N, 8.97.} \]

\[ \text{N-1-[(1R,2S,3S,4R)-2-(Methoxymethyl)-3-methoxy-4-(phosphonoxymethyl)cyclopentyl]-5'-O-[(phenylthio)phosphoryl]-2',3'-O-isopropylidenedenosine (19b).} \]

Compound 19b (90 mg, 58%) was obtained from 18b (140 mg, 0.184 mmol) as described for the synthesis of 19a: \( ^{1} \text{H-NMR (D}_{2}\text{O, 500 MHz) } \delta \text{ 8.65 (s, 1H, H-2 or H-8), 8.39 (s, 1H, H-2 or H-8), 7.12-7.30 (m, 5H, SPh), 6.30 (d, 1H, H-1’), } J_{2,1'} = 2.2 \text{ Hz), 5.32 (dd, 1H, H-2’, } J_{2,1'} = 2.2 \text{ Hz, } J_{2,2'} = 5.9 \text{ Hz), 5.01 (m, 1H, H-1’), } J_{2,1'} = 2.2 \text{ Hz, } J_{2,2'} = 5.9 \text{ Hz, } J_{2,2'} = 1.6 \text{ Hz), 4.74 (d, 1H, MOM-CH}_{2}, J = 7.1 \text{ Hz), 4.69 (m, 2H, H-4’, MOM-CH}_{2}, 4.50 (m, 1H, H-2”), 4.15 (m, 1H, H-5’a), 4.11 (m, 1H, H-5”b), 4.03 (m, 2H, H-5” x 2), 3.99 (m, 1H, H-3’), 3.54 (s, 3H, MOM-CH}_{3} \text{ or OMe), 3.26 (s, 3H, MOM-CH}_{3} \text{ or OMe), 3.18 (q, 6H, Et}_{3}\text{NCH-CH}_{3} \text{x 3, } J = 7.3 \text{ Hz), 2.71 (m, 1H, H-4”), 2.60 (m, 1H, H-6’a), 2.06 (m, 1H, H-6”b), 1.62, 1.38 (each s, each 3H, isopropylidene), 1.26 (t, 9H, Et}_{3}\text{NCH-CH}_{3} \text{x 3, } J = 7.3 \text{ Hz); }^{13} \text{C-NMR (D}_{2}\text{O, 125 MHz) } \delta \text{ 150.82, 146.42, 146.30, 143.88, 133.18, 133.14, 129.92, 129.87, 129.42, 128.25, 119.82, 119.61, 115.15, 97.02, 91.86, 86.61, 86.53, 84.62, 84.33, 81.89, 66.24, 63.67, 58.06, 56.12, 47.10, 40.69, 40.63, 26.39, 24.73, 8.68; }^{31} \text{P-NMR (D}_{2}\text{O, 202 MHz) } \delta \text{ 16.70 (s), 0.55 (s); HRMS (FAB, positive) calcd for } C_{35}H_{46}N_{5}O_{13}P_{2}S: 748.1813 \text{ (MH)+, found 748.1804; } \text{UV (H}_{2}\text{O) } \lambda_{\text{max}} = 260 \text{ nm.} \]

\[ 2'"-O-\text{Methoxymethyl-3’"-O-methyl-cyclic ADP-carbcyclic-xylose 2',3’-Acetonide (20b).} \]

Compound 20b (37 mg, 47%) was obtained from 19b (90 mg, 0.11 mmol) as described for the synthesis of 20a: \( ^{1} \text{H-NMR (D}_{2}\text{O, 500 MHz) } \delta \text{ 9.10 (s,} \]
1H, H-2 or H-8), 8.45 (s, 1H, H-2 or H-8), 6.41 (s, 1H, H-1’), 5.55 (d, 1H, H-2’, J_{2',3'} = 6.1 Hz), 5.44 (dd, 1H, H-3’, J_{3',4'} = 6.1 Hz, J_{3',2'} = 2.4 Hz), 5.02 (m, 1H, H-1”), 4.75 (d, 1H, MOM-CH$_2$, J = 6.8 Hz), 4.67 (d, 1H, MOM-CH$_2$, J = 6.8 Hz), 4.64 (m, 1H, H-4”), 4.57 (m, 1H, H-2”), 4.55 (dd, 1H, H-3’, J_{3',2'} = 6.1 Hz, J_{3',4'} = 2.4 Hz), 4.09 (m, 3H, H-5”b, H-5”b, H-3”), 4.02 (m, 1H, H-6”a), 3.98 (m, 1H, H-4”), 3.48 (s, 3H, MOM-CH$_3$ or OMe), 3.16 (s, 3H, MOM-CH$_3$ or OMe), 3.19 (q, 6H, Et$_3$NH-CH$_2$, J = 7.3 Hz), 2.94 (m, 1H, H-6”a), 2.88 (m, 1H, H-4”), 2.37 (m, 1H, H-6”b), 1.64, 1.44 (each s, 3H, isopropylidene), 1.27 (t, 9H, Et$_3$NH-CH$_3$ x 3, J = 7.3 Hz); $^{13}$C-NMR (D$_2$O, 125 MHz) δ 152.18, 145.29 144.63, 119.65, 115.10, 97.24, 92.46, 87.79, 86.93, 86.83, 85.04, 84.82, 81.87, 66.60, 64.25, 58.47, 56.24, 47.10, 36.34, 36.26, 28.41, 26.42, 24.73, 8.67;
$^{31}$P-NMR (D$_2$O, 202 MHz) δ -9.56 (d, J = 11.4 Hz), -10.46 (d, J = 11.4 Hz); HRMS (FAB, positive) calcd for C$_{22}$H$_{34}$N$_5$O$_1$P$_2$ 638.1623 (MH$^+$), found 638.1627; UV (H$_2$O) $\lambda_{max}$ 259 nm.

3”-O-Methyl-cyclic ADP-carbocyclic-xylose (5). Compound 5 (30 mg, quant.) was obtained from 20b (37 mg, 0.050 mmol) as described for the synthesis of 4: $^1$H-NMR (D$_2$O, 500 MHz, K$^+$ salt) δ 9.04 (s, 1H, H-2 or H-8), 8.41 (s, 1H, H-2 or H-8), 6.10 (d, 1H, H-1’, J_{1',2'/} = 6.1 Hz), 5.21 (m, 1H, H-2’), 4.95 (m, 1H, H-1’), 4.62 (m, 1H, H-5’a), 4.60 (m, 1H, H-3”), 4.56 (m, 1H, H-2”), 4.44 (m, 1H, H-4”), 4.11 (m, 3H, H-5”b, H-5” x 2), 4.03 (m, 1H, H-3”), 3.52 (s, 3H, OMe), 2.94 (m, 1H, H-6”a), 2.90 (m, 1H, H-4”), 2.52 (m 1H, H-6”b); $^{13}$C-NMR (D$_2$O, 125 MHz) δ 152.19, 146.69, 145.43 144.52, 120.42, 91.00, 85.77, 85.34, 81.35, 73.82, 71.18, 65.14, 63.94, 63.46, 58.59, 36.81, 27.72; $^{31}$P-NMR (D$_2$O, 202 MHz) δ -9.70 (d, J = 11.4 Hz), -10.32 (d, J = 11.4 Hz); HRMS (FAB, positive) calcd for C$_{17}$H$_{26}$N$_5$O$_1$P$_2$ 554.1048 (MH$^+$), found 554.1035; UV (H$_2$O) $\lambda_{max}$ 259 nm.

REFERENCES

1. This report constitutes Part 239 of Nucleosides and Nucleotides. Part 238: Kodama, T.; Shuto, S, Matsuda, A. Synthesis of 1’-fluoronucleosides. Submitted for publication.


![Diagram of nucleotides](attachment:figure1.png)

**FIGURE 1** cADPR (1), cADPcR (2), and the 3'-modified cADPcR analogues 3–5.
FIGURE 2  Dose-dependent Ca\(^{2+}\)-mobilizing activity of compounds in sea urchin egg homogenate. The Ca\(^{2+}\)-mobilizing activity of each compound was expressed as a percent change in ratio of fura-2 fluorescence (F340/F380) relative to that of 10 µM cADPR. The compounds examined are cADPR (1, filled circles), cADPcR (2, open circles), 3”-deoxy-cADPcR (3, open triangles), cADPcX (4, open squares), and 3”-O-methyl-cADPcX (5, open diamonds). Data are mean ± SEM of 3-6 experiments.
SCHEME 2

Reagents and conditions:  a) TIPSCI, imidazole, DMAP, DMF, rt, 91%; b) CICH₂CO₂H, DIAD, Ph₃P, toluene, 0 °C, 74%; c) NaOMe, MeOH, rt, 88%; d) 1) MOMCl, i-Pr₂NEt, CH₂Cl₂, rt, 2) TBAF, THF, rt, 97% (13a); e) 1) MeOTf, DTBMP, CH₂Cl₂, rt, 2) TBAF, THF, rt, 45% (13b); f) H₂O, reflux, quant (14a, 14b).
SCHEME 3

Reagents and conditions: a) K₂CO₃, MeOH, rt, 83% (15a), 84% (15b); b) 1) DMT-Cl, pyridine, rt, 
2) TBAF, AcOH, THF, rt, quant. (16a), quant. (16b); c) PSS, TPSCI, py, rt, 65% (17a), 62% (17b); 
d) aq. 60% AcOH, rt, 83% (18a), 88% (18b); e) 1) POCl₃, (EtO)₂PO, 0 °C, 2) H₃PO₄, Et₃N, NMM, 
pyridine, 0 °C, 46% (19a), 58% (19b); f) AgNO₃, MS 3A, Et₃N, py, rt, 46% (20a), 47% (20b); h) 
aq. 80% HCO₂H, then aq. NH₃, rt, 90% (4), quant. (5).